Teriflunomide for the treatment of relapsing–remitting multiple sclerosis: patient preference and adherence

Multiple sclerosis (MS), a chronic demyelinating neuroinflammatory disease of the central nervous system, is the most common neurological disorder leading to disability in young adulthood. In the last 2 decades, numerous treatments for relapsing–remitting MS have been approved with eleven treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Bayas, Antonios, Mäurer, Mathias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4332317/
https://www.ncbi.nlm.nih.gov/pubmed/25709412
http://dx.doi.org/10.2147/PPA.S61651

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4332317/
https://www.ncbi.nlm.nih.gov/pubmed/25709412
http://dx.doi.org/10.2147/PPA.S61651

Ejemplares similares